BIOMAT Database Logo BIOMAT Database Logo

A Concise Formal Synthesis of the Potent HIV Protease Inhibitor Nelfinavir Mesylate. 1997

Dale L. Rieger
Chemical Development, Agouron Pharmaceuticals, Inc., 3565 General Atomics Court, San Diego, California 92121.

UI MeSH Term Description Entries

Related Publications

Dale L. Rieger
Asymmetric synthesis of the potent HIV-protease inhibitor, nelfinavir.
January 2010, The Journal of organic chemistry,
Dale L. Rieger
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
November 1997, Journal of medicinal chemistry,
Dale L. Rieger
Nelfinavir mesylate: a protease inhibitor.
March 1999, The Annals of pharmacotherapy,
Dale L. Rieger
A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.
June 1998, The Journal of infectious diseases,
Dale L. Rieger
The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir.
November 2020, Cancers,
Dale L. Rieger
HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein.
August 2022, EBioMedicine,
Dale L. Rieger
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus.
June 2004, Biochemical and biophysical research communications,
Dale L. Rieger
(1S)-1-[(4R)-2,2-dimethyl-1,3-dioxolan+-4-yl][-2-hydroxyethylamm onium benzoate, a versatile building block for chiral 2-aminoalkanols: concise synthesis and application to nelfinavir, a potent HIV-protease inhibitor.
March 2000, The Journal of organic chemistry,
Dale L. Rieger
Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.
May 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Dale L. Rieger
Nelfinavir protease inhibitor study recruiting.
August 1996, AIDS treatment news,
Copied contents to your clipboard!